Abstract:Journal of Cellular and Molecular MedicineVolume 13, Issue 4 p. 758-770 Open Access AMP-activated protein kinase and pancreatic/duodenal homeobox-1 involved in insulin secretion under high leucine exposure in rat insulinoma β-cells Xiujuan Zhang, Corresponding Author Xiujuan Zhang Department of Endocrinology, Provincial Hospital affiliated to Shandong University, China *Correspondence to: Jiajun ZHAO, Department of Endocrinology, Shandong Provincial Hospital, 324 Jing 5 Rd. Jinan, Shandong Province – 250021, China.Tel.: + 86 531 85186910Fax: + 86 531 87939639E-mail: jjzhao@medmail.com.cnSearch for more papers by this authorNannan Sun, Nannan Sun Department of Endocrinology, Provincial Hospital affiliated to Shandong University, China These authors contributed equally to this study.Search for more papers by this authorLaicheng Wang, Laicheng Wang Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorHua Guo, Hua Guo Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorQingbo Guan, Qingbo Guan Department of Endocrinology, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorBin Cui, Bin Cui Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorLimin Tian, Limin Tian Department of Endocrinology, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorLing Gao, Ling Gao Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorJiajun Zhao, Corresponding Author Jiajun Zhao Department of Endocrinology, Provincial Hospital affiliated to Shandong University, China *Correspondence to: Jiajun ZHAO, Department of Endocrinology, Shandong Provincial Hospital, 324 Jing 5 Rd. Jinan, Shandong Province – 250021, China.Tel.: + 86 531 85186910Fax: + 86 531 87939639E-mail: jjzhao@medmail.com.cnSearch for more papers by this author Xiujuan Zhang, Corresponding Author Xiujuan Zhang Department of Endocrinology, Provincial Hospital affiliated to Shandong University, China *Correspondence to: Jiajun ZHAO, Department of Endocrinology, Shandong Provincial Hospital, 324 Jing 5 Rd. Jinan, Shandong Province – 250021, China.Tel.: + 86 531 85186910Fax: + 86 531 87939639E-mail: jjzhao@medmail.com.cnSearch for more papers by this authorNannan Sun, Nannan Sun Department of Endocrinology, Provincial Hospital affiliated to Shandong University, China These authors contributed equally to this study.Search for more papers by this authorLaicheng Wang, Laicheng Wang Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorHua Guo, Hua Guo Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorQingbo Guan, Qingbo Guan Department of Endocrinology, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorBin Cui, Bin Cui Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorLimin Tian, Limin Tian Department of Endocrinology, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorLing Gao, Ling Gao Department of Scientific Center, Provincial Hospital affiliated to Shandong University, ChinaSearch for more papers by this authorJiajun Zhao, Corresponding Author Jiajun Zhao Department of Endocrinology, Provincial Hospital affiliated to Shandong University, China *Correspondence to: Jiajun ZHAO, Department of Endocrinology, Shandong Provincial Hospital, 324 Jing 5 Rd. Jinan, Shandong Province – 250021, China.Tel.: + 86 531 85186910Fax: + 86 531 87939639E-mail: jjzhao@medmail.com.cnSearch for more papers by this author First published: 22 April 2009 https://doi.org/10.1111/j.1582-4934.2009.00656.xCitations: 12 AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat Abstract The effect of leucine on glucose-stimulated insulin secretion (GSIS) in pancreatic β-cells is quite controversial, and mechanism involved in the effect has not been elucidated yet. Consequently, we aimed to investigate effect of leucine on GSIS and its mechanism focusing on contribution of AMP-activated protein kinase (AMPK) and pancreatic/duodenal homeobox-1 (PDX-1). Rat insulinoma β-cells (INS-1, RIN m5F, DN-PDX-1#28 and PDX-1#6) were cultured with or without leucine, AICAR (AMPK agonist) or compound C (AMPK antagonist) for 48 hrs. In contrast to control, AICAR treatment decreased GSIS at high glucose and insulin content, also impaired protein and mRNA expression of PDX-1 and its downstream targets, glucokinase (GCK) and glucose transporter 2 (GLUT2). Compound C treatment had the opposite effects. We observed that neither AICAR nor compound C could affect expression of GCK and GLUT2 when PDX-1 expression was absent. Chronic leucine exposure inhibited GSIS at high glucose and insulin content in a dose-dependent manner, concomitant with an increase in AMPK and a decrease in PDX-1, GCK and GLUT2. The inhibitory effects of leucine was potentiated by AICAR treatment and rescued by compound C treatment. Finally, the inhibition of PDX-1 could potentiate the impaired effects induced by leucine whereas overexpression of PDX-1 could protect the cell from impairment induced by leucine. The study indicated that chronic leucine might result in an increase in AMPK and then a decrease in PDX-l, in turn to depress GCK and GLUT2 resulting in decreased GSIS at high glucose and insulin content. Introduction Recently, studies have attached great importance for the effect of leucine on glucose-stimulated insulin secretion (GSIS) and intracellular insulin content in pancreatic β-cells [1–3]. However, up to now, the results from different research groups have been quite controversial. Yang and his colleagues demonstrated that leucine was able to enhance GSIS in pancreatic β-cells [1, 2]. However Anello et al. reported that chronic leucine exposure impaired GSIS in a dose-dependent manner [3]. Moreover, the mechanism of leucine affecting insulin secretion and content has not been elucidated yet. Consequently, we aimed to investigate the effects of leucine on insulin secretion and content, also to explore the mechanism involved in the effects in rat insulinoma β-cells. AMP-activated protein kinase (AMPK) acts as a cellular energy regulator activated by increased intracellular AMP-to-ATP ratio [4, 5]. GSIS from β-cells is directly related with the generation of metabolic intermediates; therefore, AMPK is deemed as an attractive candidate for control of insulin secretion and content [6]. Many studies have reported that high glucose or fatty acid could change insulin secretion by controlling AMPK activity in pancreatic β-cells [7–10]. However, fewer studies pay attention to AMPK activity changes under chronic leucine exposure. Du and his colleagues reported that leucine stimulated mammalian target of rapamycin signalling by inhibition of AMPK activity [11], which suggested a possible association between leucine and AMPK. Glucokinase (GCK), an enzyme phosphorylating glucose to glucose-6-phosphate, acts as a glucose sensor and regulates insulin secretion [12–14]. GLUT2 is an important component for insulin secretion as well [15, 16]. Tiedge and Lenzen reported in their studies that the concordant regulation of GCK and GLUT2 genes might represent the basis regulation of GSIS [17]. In 2006, Yang et al. firstly reported that leucine culture altered GCK expression in INS-1 cells, rat islets and human islets, moreover, GCK contributed tight control of insulin secretion [1]. Though AMPK, GCK and GLUT2 were separately reported to be associated with insulin secretion, the relationship between them under leucine exposure remains unclear. Kim et al. demonstrated that AMPK could regulate GCK and GLUT2 expression at high glucose concentration [18]. On the basis of these reports, we supposed that chronic leucine exposure might influence insulin secretion and content by altering AMPK, GCK and GLUT2 expression, and there might be a regulatory relationship between AMPK, GCK and GLUT2 at high leucine concentrations. In addition, how AMPK regulates GCK or GLUT2 was worthy of being investigated. Numerous studies in vitro and in vivo have demonstrated that chronic exposure to glucose or fatty acid is able to suppress pancreatic/duodenal homeobox-1 (PDX-1) expression, leading to decreased insulin secretion [19–22]. The role of PDX-1 in pancreatic β-cell insulin secretion [23–25] derives from its effect on transactivating the expression of insulin and other β-cell-specific genes, such as GCK and GLUT2 [26–29]. This promoted us to speculate that PDX-1 might be the bridge between AMPK and GCK or GLUT2. Collectively, from these findings, we suggested that there might be a regulatory link between AMPK and PDX-1 in pancreatic β-cells exposed to leucine, in turn to affect insulin secretion and content. To test the hypothesis, we firstly examined if the regulation existed under relative physiological condition. Then, we tested the effects of elevated concentrations of leucine on insulin secretion, insulin content and the protein expression of p-AMPK, PDX-1, GCK and GLUT2. Finally, we investigated if chronic leucine exposure influenced insulin secretion and content associated with the assumed regulation (AMPK regulates GCK and GLUT2 via PDX-1). Research design and methods Cell culture and treatment Rat insulinoma (RIN) cell lines, INS-1 and RIN m5F cells (passage 20–40) were grown in monolayer culture in Roswell Park Memorial Institute (RPMI) 1640 medium (without glutamine) containing 11.1 mM glucose supplemented with 10 mM HEPES, 10% (v/v) foetal bovine serum (Invitrogen, NY USA), 1 mM sodium pyruvate, 50 μM β-mercaptoethanol, 100 IU/ml penicillin and 100 μg/ml streptomycin at 37°C in an humidified atmosphere with 5% CO2 and 95% air [28, 30]. The cells were split weekly and the medium was changed twice weekly. For the present study, INS-1 and RIN m5F cells were cultured in RPMI 1640 medium treated with either 0.5 mM AICAR [31], a widely used AMPK agonist (Toronto Research Chemicals, CA, USA), or 10 μM compound C, a AMPK antagonist (Calbiochem, San Diego, CA, USA), or supplemented with or without elevated concentrations of leucine (10, 20 or 40 mM) (Sigma, St Louis, MO, USA), for 48 hrs. Leucine was dissolved in RPMI 1640 medium and AICAR was directly dissolved in water. INS-1 stable cell lines, DN-PDX-1#28 and PDX-1#6 cells (donated by Prof. Haiyan Wang, University Medical Center, Geneva, Switzerland) were cultured in RPMI 1640 medium supplemented with 100 μg/ml hygromycin and 100 μg/ml G418 (Sigma) [21]. The first-step stable clones were INS-1 rαβ and INS-1rβ. Plasmids used in the secondary stable transfection were constructed by subcloning the cDNAs encoding the mouse Pdx1 and its dominant-negative mutant (DN-PDX-1) into the expression vector PUHD10–3 [32]. DN-PDX-1#28 cells with 500 ng/ml doxycycline (Sigma) treatment allow absent expression of wide-type PDX-1, but they can result in inducible expression of DN-PDX-1 (lacking the N-terminal 79 amino acids); on the other hand, PDX-1#6 cells with doxycycline treatment can lead to inducible overexpression of wide-type PDX-1 [33]. In the study, the cells were firstly treated with or without 500 ng/ml doxycycline for the indicated time (24, 48 and 72 hrs). Then, the cells were treated with either 0.5 mM AICAR or 10 μM compound C for 48 hrs. Insulin secretion and insulin content assays INS-1 cells (1.5 × 105/well) were firstly pre-cultured in 24-well plates in standard medium for 24 hrs, and then were treated with either 0.5 mM AICAR or 10 μM compound C, supplemented with or without elevated concentrations of leucine (10, 20 or 40 mM) for 48 hrs. Secondly, all plates of cells were gently washed twice with pre-warmed phosphate-buffered saline (PBS) and incubated in pre-warmed Krebs-Ringer bicarbonate buffer (KRB) containing 3 mM glucose for 20 min. at 37°C. Thirdly, the buffer was removed and half of the plates (in each group) were cultured in KRB containing 3 mM glucose and the left half were incubated in KRB containing 27.8 mM glucose. After an additional 20 min. incubation at 37°C, aliquots of the media were collected from each well and stored at −20°C for subsequent insulin secretion test with an insulin radioimmunoassay kit (Beijing Atom HighTech Co. Ltd., Beijing, China). To measure total protein content, the cells were treated with lysis buffer containing 1 × PBS, 1% NP40, 0.1% SDS, 5 mM ethylenediaminetetraacetic acid, 0.5% sodium deoxycholate and 1 mM sodium orthovanadate (Shenneng Bo Cai Co. Ltd, Shanghai, China). Intracellular total protein concentration was determined with a bicinchoninic acid (BCA) protein assay kit (Bio-Rad, Hercules, CA, USA). Insulin secretion was normalized based on the corresponding protein in each group. In addition, intracellular insulin contents were tested in INS-1 and RIN m5F cells, respectively. The cells were treated the same as in the insulin secretion section described. Five hundred microlitres of acid/ethanol (75% v/v ethanol, 1.5% v/v concentrated HCl) was added in each plate and incubated overnight [34]. The acid ethanol aliquots were used to measure insulin content with radioimmunoassay as described above. Total protein content was determined as described above. Insulin content was normalized based on the respective cellular protein in each group. Cell counting kit-8 (CCK-8) INS-1, RIN m5F, DN-PDX-1#28 and PDX-1#6 cells were seeded in 96-well plates at a density of 104 cells/well for 24 hrs. Then, they were treated with elevated concentrations of leucine (10, 20 or 40 mM) for 48 hrs. After that, 10 μl CCK-8 (Dojindo, Kumamoto, Japan) were added into each well and incubated for 4 hrs at 37°C in an humidified atmosphere with 5% CO2 and 95% air [35, 36] The wavelength to measure absorbance of the formazan product was 450 nm and the reference wavelength was 600 nm. Protein analysis by Western blotting The cultured INS-1, RIN m5F and DN-PDX-1#28 cells were lysed using lysis buffer supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF). Then protein extracts (60 μg total protein for GCK/GLUT2 and 40 μg protein for PDX-1) were separated by SDS-PAGE and transferred onto nitrocellulose membranes (Millipore, Billerica, MA, USA). Membranes were gently shaked overnight at 4°C with 1:1000 p-AMPK antibody (Cell Signalling, Danvers, MA, USA), 1:10,000 PDX-1 antibody (Chemicon, Billerica, MA, USA), 1:200 GCK antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or 1:200 GLUT2 antibody (Santa Cruz Biotechnology). After the membranes were incubated with the corresponding second antibody at room temperature for 1 hr, proteins were visualized by enhanced chemiluminescence (Amersham Biosciences UK Limited, Little Chalfont, UK). The same membrane was re-blocked with 5% non-fat milk and incubated with mouse 1:10,000 β-actin monoclonal antibody (Abcam, Cambridge, UK). Immunoreactive bands were quantified by image analyzer Alphaimager 2200 (Alpha Innotech, San Leandro, CA, USA). RNA isolation and real-time PCR Total RNA was isolated from INS-1, RIN m5F, DN-PDX-1#28 and PDX-1#6 cells (1 × 106 cells/ well) with TRIzol (Invitrogen Corp., Carlsbad, CA, USA) method. In brief, 3 μg RNA isolated from each sample was used as the template in each reverse transcription reaction to generate first-strand cDNA using oligo (dT)18 as primer according to Fermentas RT kit (Fermentas, Glen Burnie, MD, USA). The cDNA was amplified by real-time PCR [37] using a QuantiTect SYBR Green kit (TaKaRa, Otsu, Shiga, Japan) and the ABI 7500 Prism real-time PCR instrument and software (Prism 7500; Applied Biosystems Inc., Foster city, CA, USA). All quantifications were performed with rat β-actin as an internal. Primer sequences used in the PCR are provided in Table 1. The PCR was performed for 40 cycles at 95°C for 15 sec., 60°C for 30 sec. and 72°C for 34 sec. The relative quantification of gene expression was analyzed by the 2−ΔΔCt method [38] and the results were expressed as extent of change with respect to control values. Table 1. Sequence information on the primers used for real-time PCR Genes Sequences Products size (bp) Annealing temperature (C) Gene bank PDX-1 5′-AAACGCCACACACCAAGGAGAA-3′ 5′-AGACCTGGCGGTTCACATG-3′ 150 60 NM_022852 GCK 5′-GCTTTTGAGACCCGTTTCGT-3′ 5′-CGCACAATGTCGCAGTCG-3′ 119 60 NMJD12565 GLUT2 5′-CAGCTGTCTCTGTGCTGCTTGT-3′ 5′-GCCGTCATGCTCACATAACTCA-3′ 150 60 NM_012879 ACTIN 5′-CGCATCCTCTTCCTCCCTG-3′ 5′-GCCACAGGATTCCATACCCA-3′ 130 60 NM_031144 Statistical analysis All of the experiments were repeated at least three independent times. All values are given as mean ± S.D. Data were analyzed using SPSS 11.5 software (SPSS, Inc., Chicago, IL, USA). Statistical significance was assessed by one-way anova. The difference was considered significant if the P-value was less than 0.05. Results The effects of AICAR or compound C in INS-1 and RIN m5F cells To test the regulatory role of AMPK on PDX-1, GCK and GLUT2, INS-1 and RIN m5F cells were cultured with or without 0.5 mM AICAR or 10 μM compound C for 48 hrs. We firstly performed radioimmunoassay for insulin secretion and content detection. The results showed that in contrast to control, AICAR treatment decreased GSIS at high glucose by 29% (Fig. 1A, P < 0.05) and reduced the intracellular insulin content by 30% (Fig. 1B, P < 0.05) in INS-1 cells. In RIN m5F cells, after 48 hrs of AICAR incubation, there is a 34% decrease in the intracellular content compared with control (Fig. 1B, P < 0.05). When AMPK activity was inhibited by compound C, the results were quite opposite. In comparison with the corresponding control, compound C treatment was able to enhance GSIS at high glucose by 17% in INS-1 cells (Fig. 1A, P < 0.05) and the intracellular insulin content by 19% in INS-1 cells (Fig. 1B, P < 0.05) and 25% in RIN m5F (Fig. 1B, P < 0.05). However, neither AICAR nor compound C could affect the insulin secretion level at low glucose (3 mM) stimulation (Fig. 1A, P > 0.05) in INS-1 cells. The results revealed that AMPK played an important role in manipulating high glucose-induced insulin secretion and intracellular insulin content. Figure 1Open in figure viewerPowerPoint The effects of AICAR or compound C in β-cells. INS-1 and RIN m5F cells were cultured in RPMI 1640 with or without 0.5 mM AICAR or 10μM compound C for 48 hrs. Insulin secretion (A) at 3 mM glucose (□) and 27.8 mM glucose (▪) in INS-1 cells and intracellular insulin content (B) in INS-1 cells and RIN m5F cells were determined by radioimmunoas-say. The values were normalized by the intracellular protein content. The effects of AICAR or compound C on PDX-1, GCK and GLUT2 protein expression was tested by Western blotting in INS-1 cells (C) and RIN m5F cells (D). The mRNA expression of PDX-1, GCK and GLUT2 in INS-1 cells (E) and RIN m5F cells (F) was tested by real-time PCR. The data are the means ± S.D. All the values were collected from at least three separate experiments. *, #, X and &, P< 0.05, versus the corresponding control group. Then, Western blotting and real-time PCR were used for p-AMPK, PDX-1, GCK and GLUT2 examination. In contrast to control, AICAR significantly strengthened the band of p-AMPK and weakened the bands of PDX-1 and its downstream targets, GCK and GLUT2 in INS-1 (Fig. 1C, P < 0.05) and RIN m5F cells (Fig. 1D, P < 0.05). Compared to the corresponding control, compound C obviously decreased AMPK activity and showed enhanced bands of PDX-1, GCK and GLUT2 in INS-1 (Fig. 1C, P < 0.05) and RIN m5F cells (Fig. 1D, P < 0.05). The results were confirmed by real-time PCR as well. Compared to the corresponding control, AICAR decreased PDX-1 mRNA levels by 38% and 31%, GCK mRNA levels by 21% and 57%, GLUT2 mRNA levels by 51% and 44% in INS-1 cells (Fig. 1E, P < 0.05) and RIN m5F cells (Fig. 1F, P < 0.05), respectively. In contrast to the corresponding control, compound C increased PDX-1 mRNA levels by 36% and 55%, GCK mRNA levels by 23% and 24%, GLUT2 mRNA levels by 30% and 40% in INS-1 (Fig. 1E, P < 0.05) and RIN m5F cells (Fig. 1F, P < 0.05), respectively. The effects of AICAR or compound C in DN-PDX-1#28 cells When DN-PDX-1#28 cells were treated with or without 500 ng/ml doxycycline for 24, 48 and 72 hrs, our results revealed a time-dependent expression of PDX-1 protein in DN-PDX-1#28 cells. Under non-induced condition (without 500 ng/ml doxycycline treatment), the PDX-1 protein expression showed a stained band and there was no significant difference between 24 and 48 or 72 hrs (Fig. 2A, P > 0.05). Under induced condition (with 500 ng/ml doxycycline treatment), PDX-1 protein band became weaker with time extension; furthermore, the weakest bands occurred in cells treated with doxycycline for 72 hrs (Fig. 2A, P < 0.05). Consistent with this, GLUT2 and GCK expression had the similar diminishing consequence with PDX-1 described above. Under non-induced condition for 24, 48 and 72 hrs, protein bands intensity of both GCK and GLUT2 presented no change (Fig. 2B, P > 0.05). Under induced condition for 24, 48 and 72 hrs, there was parallel decrease in the protein expression of GCK and GLUT2 (Fig. 2B, P < 0.05). The results suggested that PDX-1 performed its function well in the regulation of GCK and GLUT2. Figure 2Open in figure viewerPowerPoint The effects of AICAR or compound C in DN-PDX-1#28 cells. DN-PDX-1#28 cells were treated with or without 500 ng/ml doxycycline for 24, 48 and 72 hrs. Western blotting was performed to detect the protein expression of PDX-1 (A), GCK and GLUT2 (B). The results were obtained from at least three independent experiments. *, # and X, P< 0.05, versus the corresponding control group. In order to confirm the function of PDX-1 in the process of AMPK regulating GCK and GLUT2, DN-PDX-1#28 cells were pre-treated with or without 500 ng/ml doxycycline for 24 hrs prior to treatment with or without AICAR or compound C for a further 48 hrs. Radioimmunoassay, Western blotting and real-time PCR were performed for the detection. In comparison with control, doxycycline alone treatment obviously decreased high glucose-induced insulin secretion by 88% (Fig. 3A1, P < 0.05), insulin content by 82% (Fig. 3A2, P < 0.05), and compound C alone treatment significantly increased high glucose-induced insulin secretion by 17% (Fig. 3A1, P < 0.05) and insulin content by 19% (Fig. 3A2, P < 0.05). However, compared with doxycycline alone treatment, doxycycline plus compound C treatment could not significantly affect insulin secretion or content (Fig. 3A, P > 0.05). With regard to p-AMPK, PDX-1, GCK and GLUT2 protein expression changes, under non-induced condition, AICAR or compound C had the same effects as those observed in INS-1 cells described in Fig. 1C or RIN m5F cells in Fig. 1D (Fig. 3B). However, under induced condition, p-AMPK protein expression had the same result as that under non-induced condition (Fig. 3B); with regard to PDX-1, GCK or GLUT2 protein expression, neither AICAR nor compound C could affect them (Fig. 3B, P > 0.05). The results were confirmed by real-time PCR (Fig. 3C) as well. Figure 3Open in figure viewerPowerPoint Neither AICAR nor compound C could affect GCK and GLUT2 expression when PDX-1 expression was absent. DN-PDX-1#28 cells were pre-treated with or without 500 ng/ml doxycycline for 24 hrs prior to treatment with or without 0.5 mM AICAR or 10 μM compound C for a further 48 hrs. Insulin secretion (A1) at 3 mM glucose (□) and 27.8 mM glucose (▪) and insulin content (A2) were determined by radioimmunoassay. The values were normalized by the intracellular protein content. The PDX-1, GCK and GLUT2 protein and mRNA expression were determined by Western blotting (B) and real-time PCR (C). The data are the means ± S.D. All results were collected from at least three separate experiments. *, #, X and &, P< 0.05, versus the corresponding control group. a, b and c, P > 0.05, versus the doxycycline alone treatment group. The effects of elevated concentrations of leucine in INS-1 and RIN m5F cells To obtain insight into the functional changes when exposed to elevated concentrations of leucine, INS-1 and RIN m5F cells were cultured with or without elevated levels of leucine for 48 hrs. The cells were then used to determine insulin secretion as well as intracellular insulin content. As shown in Fig. 4A and B, our results demonstrated that a 48-hr incubation with elevated concentrations of leucine led to a dose-dependent decrease of GSIS at high glucose in INS-1 cells and insulin content in both INS-1 and RIN m5F cells. In INS-1 cells, in comparison with control, 40 mM leucine exposure significantly decreased high glucose-induced insulin secretion by 34% (Fig. 4A, P < 0.05) and diminished the intracellular insulin content by 24% (Fig. 4B, P < 0.05), respectively, and there was not apparent change in insulin secretion induced by low glucose stimulation in INS-1 cells (Fig. 4A, P > 0.05). There was no difference in insulin secretion at both low and high glucose stimulation between control and either 10 mM or 20 mM leucine treatment (Fig. 4A, P > 0.05), and the same results occurred in insulin content as well in INS-1 cells (Fig. 4B, P > 0.05). With regard to RIN m5F cells, the insulin content presented the same trend as in INS-1 cells, 40 mM leucine diminished the intracellular insulin content by 24% (Fig. 4B, P < 0.05) in contrast to its control. Western blotting and real-time PCR were performed for p-AMPK, PDX-1, GCK and GLUT2 detection. In contrast to control, 40 mM leucine exposure significantly enhanced p-AMPK protein expression in INS-1 cells (Fig. 4C, P < 0.05) and RIN m5F cells (Fig. 4D, P < 0.05). The protein levels of PDX-1 and its downstream targets, GCK and GLUT2 in 40 mM leucine-treated cells were much lower than those in cells that were cultured in leucine-absent media in INS-1 cells (Fig. 4C, P < 0.05) and RIN m5F cells (Fig. 4D, P < 0.05). Compared with control, neither 10 mM nor 20 mM leucine culture could statistically change the expression of those proteins described above in INS-1 cells (Fig. 4C, P > 0.05) and RIN m5F cells (Fig. 4D, P > 0.05). The results above were confirmed by real-time PCR (Fig. 4E and F) as well. Figure 4Open in figure viewerPowerPoint The effects of elevated concentrations of leucine in β-cells. INS-1 and RIN m5F cells were treated with or without elevated concentrations of leucine (10, 20 or 40 mM) for 48 hrs. Insulin secretion (A) at 3 mM glucose (□) and 27.8 mM glucose (▪) in INS-1 cells and intracellular insulin content in INS-1 (B) and RIN m5F cells (B) were determined by radioimmunoassay. The values were adjusted by the intracellular protein content. The protein expression of p-AMPK, PDX-1, GCK and GLUT2 in INS-1 cells (C) and RIN m5F cells (D) was detected by Western blotting. The mRNA expression of PDX-1, GCK and GLUT2 in INS-1 cells (E) and RIN m5F cells (F) was tested using real-time PCR. The data are the means ± S.D. The results were based from at least three separate experiments. *, #, X and &, P< 0.05, versus the corresponding control group. Leucine cytotoxicity detection on pancreatic β-cell lines In order to further testify that 40 mM leucine was appropriate for the experiment research, INS-1, RIN m5F, DN-PDX-1#28 and PDX-1#6 cells were firstly treated with or without elevated concentrations of leucine and then tested the cell viability by CCK-8 method, respectively. The results showed that in INS-1, RIN m5F, DN-PDX-1#28 and PDX-1#6 cells, compared with their corresponding controls, the cell viability of 10 mM leucine was 99% (Fig. 5A, P > 0.05), 97% (Fig. 5B, P > 0.05), 98% (Fig. 5C, P > 0.05), 98% (Fig. 5D, P > 0.05), the cell viability of 20 mM leucine was 98% (Fig. 5A, P > 0.05), 97% (Fig. 5B, P > 0.05), 98% (Fig. 5C, P > 0.05), 99% (Fig. 5D, P > 0.05), the cell viability of 40 mM leucine was 97% (Fig. 5A, P > 0.05), 97% (Fig. 5B, P > 0.05), 96% (Fig. 5C, P > 0.05), 95% (Fig. 5D, P > 0.05). The results testified that neither 10, nor 20 nor 40 mM leucine had cytotoxicity on pancreatic β-cell lines. Figure 5Open in figure viewerPowerPoint Leucine cytotoxicity detection on pancreatic β-cell lines. INS-1, RIN m5F, DN-PDX-1#28 and PDX-1#6 cells were treated with or without elevated concentrations of leucine (10 mM, 20 mM, 40 mM) for 48 hrs. Then, the cell viability in INS-1 (A), RIN m5F (B), DN-PDX-1#28 (C) and PDX-1#6 cells (D) was evaluated using CCK-8. The data are the means ± S.D. All the results were collected from at least three separate experiments. The effects of AICAR or compound C in INS-1 and RIN m5F cells with chronic leucine treatment INS-1 and RIN m5F cells were incubated in RPMI 1640 media supplemented with or without 40 mM leucine, in the presence or absence of AICAR or compound C for 48 hrs. In INS-1 and RIN m5F cells, either leucine alone, AICAR alone or compound C alone treatment induced the same results as the data from Figs. 1 and 4. Moreover, in comparison with leucine treatmen

Leucine Facilitates Insulin Signaling through a Gαi Protein-dependent Signaling Pathway in Hepatocytes

Leucine Facilitates the Insulin-Stimulated Glucose Uptake and Insulin Signaling in Skeletal Muscle Cells: Involving Mtorc1 and Mtorc2.

Leucine Deprivation Increases Hepatic Insulin Sensitivity Via GCN2/mTOR/S6K1 and AMPK Pathways.

Agonist-induced activation of human FFA1 receptor signals to extracellular signal-regulated kinase 1 and 2 through Gq- and Gi-coupled signaling cascades

Leucine metabolism in regulation of insulin secretion from pancreatic beta cells: Nutrition Reviews©, Vol. 68, No. 5

Leucine suppresses α-cell cAMP and glucagon secretion via a combination of cell-intrinsic and islet paracrine signaling

Chronic Leucine Supplementation Increases Body Weight and Insulin Sensitivity in Rats on High-Fat Diet Likely by Promoting Insulin Signaling in Insulin-Target Tissues

Leucine Promotes Leptin Receptor Expression in Mouse C2C12 Myotubes Through the Mtor Pathway.

Leucine Supplementation Increases SIRT1 Expression and Prevents Mitochondrial Dysfunction and Metabolic Disorders in High-Fat Diet-Induced Obese Mice.

Leucine Supplementation Differently Modulates Branched-Chain Amino Acid Catabolism, Mitochondrial Function and Metabolic Profiles at the Different Stage of Insulin Resistance in Rats on High-Fat Diet.

Leucine supplementation improves leptin sensitivity in high-fat diet fed rats

Leucine Regulation of Glucokinase and ATP Synthase Sensitizes Glucose-Induced Insulin Secretion in Pancreatic Beta-Cells.

AMP-Activated Protein Kinase and Pancreatic/Duodenal Homeobox-1 Involved in Insulin Secretion under High Leucine Exposure in Rat Insulinoma Β-Cells

EFFECT OF LEUCINE ON INSULIN SENSITIVITY IN RATS FED A HIGH-FAT DIET

l -Leucine and NO-mediated cardiovascular function

Chronic Leucine Exposure Results in Reduced but Reversible Glucose-Stimulated Insulin Secretion in Ins-1 Cells

Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms

Upregulation of Amino Acid Transporter Expression Induced by L-leucine Availability in L6 Myotubes is Associated with ATF4 Signaling Through Mtorc1-Dependent Mechanism.

KIC (ketoisocaproic acid) and leucine have divergent effects on tissue insulin signaling but not on whole-body insulin sensitivity in rats

Leucine Stimulates ASCT2 Amino Acid Transporter Expression in Porcine Jejunal Epithelial Cell Line (IPEC-J2) Through PI3K/Akt/mTOR and ERK Signaling Pathways.

LRP1 facilitates hepatic glycogenesis by improving the insulin signaling pathway in HFD-fed mice